Charles River Laboratories International, Inc. (CRL)
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago.
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River is Placed Just Ahead of Q1 Earnings
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, with a risk-adjusted U.S. revenue potential of $216 million annually.
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
It's been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic slowdown.
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy
Aldeyra Therapeutics' stock plummeted 74% due to an FDA Complete Response Letter for reproxalap but presents a favorable risk-reward for speculative investors. Despite past setbacks, ALDX's history of resilience and upcoming trial results offer potential catalysts for recovery, with minimal near-term dilution risk. ALDX's strong cash position and reduced burn rate provide a safety net, with significant upside potential if reproxalap trials succeed and FDA approval is achieved.
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Deciphering Charles River (CRL) International Revenue Trends
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
